TPM3 and colorectal carcinoma: Based on these promising preclinical data and phase I results, TRKA-selected CRC patients are currently being enrolled in the open-label, multicenter global phase II basket study of entrectinib, an orally available pan-TRK, ROS1 and ALK inhibitor.